Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Alternative Erythropoietin Receptors in the Nervous System.

Ostrowski D, Heinrich R.

J Clin Med. 2018 Feb 2;7(2). pii: E24. doi: 10.3390/jcm7020024. Review.

2.

Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor.

Miao S, Wang SM, Cheng X, Li YF, Zhang QS, Li G, He SQ, Chen XP, Wu P.

Cancer Cell Int. 2017 Dec 11;17:119. doi: 10.1186/s12935-017-0494-7. eCollection 2017.

3.

Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells.

Merkle R, Steiert B, Salopiata F, Depner S, Raue A, Iwamoto N, Schelker M, Hass H, Wäsch M, Böhm ME, Mücke O, Lipka DB, Plass C, Lehmann WD, Kreutz C, Timmer J, Schilling M, Klingmüller U.

PLoS Comput Biol. 2016 Aug 5;12(8):e1005049. doi: 10.1371/journal.pcbi.1005049. eCollection 2016 Aug.

4.

Widespread expression of erythropoietin receptor in brain and its induction by injury.

Ott C, Martens H, Hassouna I, Oliveira B, Erck C, Zafeiriou MP, Peteri UK, Hesse D, Gerhart S, Altas B, Kolbow T, Stadler H, Kawabe H, Zimmermann WH, Nave KA, Schulz-Schaeffer W, Jahn O, Ehrenreich H.

Mol Med. 2015 Sep 1. doi: 10.2119/molmed.2015.00192. [Epub ahead of print]

5.

Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma.

Meyer FR, Steinborn R, Grausgruber H, Wolfesberger B, Walter I.

Vet J. 2015 Oct;206(1):67-74. doi: 10.1016/j.tvjl.2015.06.003. Epub 2015 Jun 6.

6.

Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.

Patterson SD, Rossi JM, Paweletz KL, Fitzpatrick VD, Begley CG, Busse L, Elliott S, McCaffery I.

PLoS One. 2015 Mar 25;10(3):e0122149. doi: 10.1371/journal.pone.0122149. eCollection 2015.

7.

Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.

Rózsás A, Berta J, Rojkó L, Horváth LZ, Keszthelyi M, Kenessey I, László V, Berger W, Grusch M, Hoda MA, Török S, Klepetko W, Rényi-Vámos F, Hegedűs B, Döme B, Tóvári J.

PLoS One. 2013 Oct 14;8(10):e77459. doi: 10.1371/journal.pone.0077459. eCollection 2013.

8.

Epo receptors are not detectable in primary human tumor tissue samples.

Elliott S, Swift S, Busse L, Scully S, Van G, Rossi J, Johnson C.

PLoS One. 2013 Jul 4;8(7):e68083. doi: 10.1371/journal.pone.0068083. Print 2013.

9.

Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development.

Moriconi F, Ramadori P, Schultze FC, Blaschke M, Amanzada A, Khan S, Ramadori G.

Histochem Cell Biol. 2013 Mar;139(3):473-85. doi: 10.1007/s00418-012-1037-x. Epub 2012 Oct 4.

10.

The effect of erythropoietin on normal and neoplastic cells.

Elliott S, Sinclair AM.

Biologics. 2012;6:163-89. doi: 10.2147/BTT.S32281. Epub 2012 Jun 27.

11.

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.

Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B.

Br J Cancer. 2012 Mar 27;106(7):1249-58. doi: 10.1038/bjc.2012.42. Epub 2012 Mar 6. Review.

12.

Potential prognostic marker ubiquitin carboxyl-terminal hydrolase-L1 does not predict patient survival in non-small cell lung carcinoma.

Orr KS, Shi Z, Brown WM, O'Hagan KA, Lappin TR, Maxwell P, Percy MJ.

J Exp Clin Cancer Res. 2011 Aug 30;30:79. doi: 10.1186/1756-9966-30-79.

14.

Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O.

Arch Intern Med. 2010 Sep 13;170(16):1490-8. doi: 10.1001/archinternmed.2010.309. Review.

15.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H.

Br J Cancer. 2010 Jan 19;102(2):301-15. doi: 10.1038/sj.bjc.6605498. Epub 2010 Jan 5.

16.

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD, Watson JE, Arnold GE, Nguyen KC, Powers S, Elliott S.

Br J Cancer. 2008 Mar 25;98(6):1059-67. doi: 10.1038/sj.bjc.6604220. Epub 2008 Mar 18.

17.

Effects of recombinant erythropoietin on breast cancer-initiating cells.

Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F.

Neoplasia. 2007 Dec;9(12):1122-9. Review.

18.

Erythropoiesis stimulating agents.

Steensma DP.

BMJ. 2007 Mar 31;334(7595):648-9. No abstract available.

Supplemental Content

Support Center